BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 3329524)

  • 21. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
    Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
    Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.
    Lobert S; Boyd CA; Correia JJ
    Biophys J; 1997 Jan; 72(1):416-27. PubMed ID: 8994628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered molecular properties of tubulin in a multidrug-resistant variant of Chinese hamster cells selected for resistance to vinca alkaloids.
    Pain J; Sirotnak FM; Barrueco JR; Yang CH; Biedler JL
    J Cell Physiol; 1988 Aug; 136(2):341-7. PubMed ID: 3045133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules.
    Himes RH
    Pharmacol Ther; 1991; 51(2):257-67. PubMed ID: 1784631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The thermodynamics of vinca alkaloid-induced tubulin spirals formation.
    Lobert S; Ingram JW; Correia JJ
    Biophys Chem; 2007 Mar; 126(1-3):50-8. PubMed ID: 16757093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT; Cirtain MC; Look AT; Ashmun RA
    Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: paracrystal formation by Vinca alkaloids.
    Müller LJ; Moorer-van Delft CM; Roubos EW
    Cancer Res; 1988 Dec; 48(24 Pt 1):7184-8. PubMed ID: 3191492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vinca alkaloid and MDR1].
    Takigawa N; Tanimoto M
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1086-9. PubMed ID: 18633246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication.
    Grellier P; Sinou V; Garreau-de Loubresse N; Bylèn E; Boulard Y; Schrével J
    Cell Motil Cytoskeleton; 1999; 42(1):36-47. PubMed ID: 9915583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
    Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
    Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
    Ngo QA; Roussi F; Cormier A; Thoret S; Knossow M; Guénard D; Guéritte F
    J Med Chem; 2009 Jan; 52(1):134-42. PubMed ID: 19072542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhazinilam mimics the cellular effects of taxol by different mechanisms of action.
    David B; Sévenet T; Morgat M; Guénard G; Moisand A; Tollon Y; Thoison O; Wright M
    Cell Motil Cytoskeleton; 1994; 28(4):317-26. PubMed ID: 7954858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y; Yang SH; Guo XL
    Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro.
    Donoso JA; Green LS; Heller-Bettinger IE; Samson FE
    Cancer Res; 1977 May; 37(5):1401-7. PubMed ID: 558047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel aspects of natural and modified vinca alkaloids.
    Duflos A; Kruczynski A; Barret JM
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro inhibition of microtubule assembly by disulfiram.
    Potchoo Y; Braguer D; Peyrot V; Chauvet-Monges AM; Sari JC; Crevat A
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):499-504. PubMed ID: 3781685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.